Both acute and chronic neurotoxicities are well-described with the use of oxaliplatin. We describe the case of a 50-year-old man with Dukes C colon carcinoma being treated with an adjuvant FOLFOX4 (5-fluorouracil, leucovorin and oxaliplatin (85 mg/m2 per cycle)) who developed a widespread acute pain 5 min after commencing his twelfth cycle of chemotherapy. The pain was disabling and distressing, and remained for 16 h despite multimodality analgesia. The patient was not rechallenged with oxaliplatin. We believe this presentation represents an acute neurological phenomenon relating to oxaliplatin. Of note, this acute reaction occurred after 11 cycles of treatment, significantly later in the treatment course than other reports of atypical acute reactions.
de GramontAFigerASeymourM. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000; 18(16): 2938–2947.
2.
GoldbergRMSargentDJMortonRF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic CRC. J Clin Oncol2004; 22(1): 23–30.
3.
ColucciGGebbiaVPaolettiG. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol2005; 23(22): 4866–4875.
4.
GoldbergRMSargentDJMortonRF. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American intergroup trial. J Clin Oncol2006; 24(21): 3347–3353.
5.
AndreTBoniCMounedji-BoudiafL. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med2004; 350(23): 2343–2351.
6.
CunninghamDStarlingNRaoS. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med2008; 358(1): 36–46.
7.
ConroyTDesseigneFYchouM. Randomized Phase III trial comparing FOLFIRINOX versus gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma: preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial [abstract]. J Clin Oncol2010; 28(suppl 7s): Abstract 4010–Abstract 4010.
8.
CassidyJMissetJL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol2002; 29(suppl 15): 11–20.
9.
GamelinEGamelinLBossiLQuasthoffS. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventative measures. Semin Oncol2002; 29(suppl 15): 21–33.
GrolleauFGamelinLBoisdron-CelleM. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol2001; 85: 2293–2297.
12.
WebsterRBrainKWilsonR. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol2005; 146: 1027–1039.
13.
AdelsbergerHQuasthoffSGrosskreutzJ. The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons. Euro J Pharmacol2000; 406: 25–32.
ParkSGoldsteinDLinC. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol2009; 27: 1243–1249.
16.
SaadatiHSaifM. Oxaliplatin-induced hyperexcitability syndrome in a patient with pancreatic cancer. J Pancreas2009; 10(4): 459–461.
17.
SaifMHashmiS. Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemother Pharmacol2008; 61: 349–354.
18.
UnaE. Atypical presentation of acute neurotoxicity secondary to oxaliplatin. J Oncol Pharm Practice2010; 16: 280–282.
19.
WinquistEVincentMStadlerW. Acute bilateral abducens paralysis due to oxaliplatin. J Natl Cancer I2003; 95: 488–489.
20.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30(2): 239–245.
21.
PetrioliRPascussiAFranciniE. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol2008; 61: 105–111.
22.
HochsterHGrotheyAChildsB. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Onc2007; 25: 4028–4029.
23.
Hochster H, Grothey A, Shpilsky A and Childs B. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on reponse to FOLFOX+bevacizumab (BEV) in the CONcePT trial. Abstract 280, 2008. In: ASCO Gastrointestinal Cancers Symposium, Orlando, Florida, USA, 25–27 Jan 2008.
24.
KurnialiPLuoLWeitbergA. Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. Oncology2010; 24(3): 289–292.
25.
PasettoLD’AndreaMRossiEMonfardiniS. Oxaliplatin-related neurotoxicity: how and why?. Crit Rev Onc Hem2006; 59: 159–168.
